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Abstract This commentary is a face-to-face debate
between two almost opposite positions regarding the
application of genetic engineering in agriculture and food
production. Seven questions on the potential benefits of the
application of genetic engineering in agriculture and on the
potentially adverse impacts on the environment and human
health were posed to two scientists: one who is sceptical
about the use of GMOs in Agriculture, and one who views
GMOs as an important tool for quantitatively and qualita-
tively improving food production.
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Since the mid-1990s, the release of GMOs into the environ-
ment and the marketing of foods derived from GM crops has
resulted in a scientific and public debate. Despite the potential
benefits of the application of genetic engineering in agricul-
ture in order to improve the quality and the reliability of the
food supply, since the beginning, public and scientific con-
cerns have been raised in many parts of the world about
environmental and food safety of GM crops.
Two major different points of view have been expressed
by the community: on one hand, recombinant DNA tech-
nology is seen as a potent tool for enhancing crop pro-
ductivity (first generation GMOs) and food quality (second
generation GMOs) or ‘‘drug factories’’, for the production
of vaccines and/or therapeutic medicines (third generation
GMOs). GMO supporters point to evidence that GMOs
must be considered essential for promoting sustainable
agriculture, as they may be able to reduce agriculture’s
environmental footprint, reducing the use of pesticides,
saving fossil fuels, decreasing CO2 emissions and con-
serving soil and moisture (James 2011). Supporters also
consider GM crops indispensable in facing the severe
global food and nutrition security problem in developing
countries: although GM crops are not presented as the
‘‘absolute solution’’, it has been stated that they could
undoubtedly make a significant contribution to an array of
measurements and incentives to this constantly growing
problem (Conner et al. 2003).
On the other hand, antagonists argued that the side
effects in terms of potentially adverse impacts on the
environment and human health are still largely unknown,
and probably unknowable for decades, and encourage
waiting for the final outcome of further research and utili-
zation. Many concerns have been raised for the environ-
ment: the capability of a GMO to escape from confinement
and therefore potentially to transfer engineered genes into
wild populations, the persistence of the gene after a GMO
has been harvested, the susceptibility of non-target organ-
isms to the gene product, the instability of new genes, the
reduction of the spectrum of other plants resulting in a
significant loss of biodiversity and an increase in the use of
chemicals in agriculture. As for human health, the main
concerns have been the possibility of a transfer of allergens
into the new foods, the gene transfer from GM foods to
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human cells or to bacteria in the gastrointestinal tract, which
can cause worries especially transferred genetic material
proved to adversely affect human health the transfer of
genes from GM plants into conventional crops or related
species in the wild, as well as the mixing of GM crops with
those derived from conventional seeds, that could have an
indirect effect on food safety and food security.
The same debate also occurs at the societal level. It is
obvious that without ‘‘approval’’ by society at large, GM
crops will surely fail in the marketplace. The forthcoming
years, then, will be crucial for the commercial and eco-
nomically viable application of GMOs in agriculture and
food production (Nap et al. 2003). Consumer attitudes with
respect to genetically modified foods differ widely, par-
ticularly between North America and Europe. Information
asymmetry, incomplete information and uncertainty arise
as a result of concerns over GMOs. The major concerns
have arisen particularly in western Europe, where a general
lack of awareness about how our food production system
evolved, the strong opposition by activist groups and a
steady stream of negative opinions in the media rapidly
increased the resistance to GMO production and use among
consumers. This point of view was rapidly endorsed by
politicians. The European consumer confidence in the
safety of food supplies had decreased significantly in the
1990s as a result of a number of food ‘‘scandals’’ that,
although not related to GM foods, left consumers to a state
of uncertainty regarding the validity of risk assessments,
both with regard to consumer health and environmental
risks, focusing in particular on long-term effects.
With regard to foods derived from GM crops, consumers
have not perceived any direct advantage, and therefore the
public attention focused on the risk side of the risk–benefit
equation.
As a consequence of the different American and Euro-
pean public attitudes towards this technology and the foods
produced, the regulatory approaches in Europe and North
America are essentially different: in the EU regulatory
policy is based on the process of making GM crops; in the
USA on the characteristic of the GM product.
In the EU, strong public concerns about GMOs triggered
the imposition in October 1998 of a de facto moratorium
on the authorization of new releases of GMOs in the
European Union, and even stricter standards were proposed
in the EU’s revised Directive 90/220 of August 2000.
Before the imposition of the moratorium, releases of
GMOs were reviewed on a case-by-case basis and had to
be approved at every step from laboratory testing through
field testing to final marketing. By contrast, the permit
procedure in the United States is far simpler and faster.
Consumer concerns have triggered a discussion on the
desirability of labelling GM foods, allowing an informed
choice. The different attitudes of the consumers in EU and
USA have led to marked differences in national labelling
requirements. The US Food and Drug Administration does
not require labelling of GM foods per se, but only if the
transgenic food is substantially different from its conven-
tional counterpart. The EU, by contrast, requires labelling
of all foodstuffs, additives and flavours containing 1 % or
more genetically modified material (Regulations 1139/98
and 49/2000).
Within this picture, seven different questions were posed
to two scientists representing the two different points of
view: Prof. Marcello Buiatti (Dept of Genetics at the
University of Florence, Italy), who is sceptical about the
use of GMOs in agriculture, and Prof. Paul Christou (Dept.
of Plant Production and Forestery Sciences, University of
Lleida, Spain), who represents those who view GMOs as
an important tool for quantitatively and qualitatively
improving food production.
1. Concerns have been raised that GM crops will
hybridize with related species resulting in the intro-
gression of transgenes to weedy relatives. For trans-
genes conferring resistance to pests, diseases and
herbicides, it has been suggested that this can also lead
to an enhanced fitness, survival and spread of weeds.
On the other hand, GM crops have been proposed as
‘‘friendly’’ bioherbicides and bioinsecticides, suggest-
ing that future GMOs will be useful for soil, water, and
energy conservation and for the natural waste man-
agement. Are GMOs, then, a risk or an opportunity to
maintain the health of the environment?
M. Buiatti:
I do not really see at this moment any possible advan-
tage from GMO cultivation for the health of the environ-
ment. I do not really remember reductions in tillage
practices favorable to the environment, as the only reduced
practice is man-made weed destruction, certainly advan-
tageous for the owners of the fields because of the very low
level of manpower needed in the case of herbicide resistant
crops, but of irrelevant as far as environment management
is concerned. Moreover, as the herbicide can in this case be
utilized all along the cycle, many more treatments can be
carried out and it is widely known that glyphosate exerts
detrimental effects on the soil ecosystem and may be pol-
luting ground water.
On the other hand, transgene flow to weedy relatives
particularly of canola, an outbreeding species liable to
hybridize to other Brassicaceae (Beckie et al. 2009), and of
maize in the area of the origin of the species, has been
shown to occur (see for instance Snow 2009). However,
only the maize case is relevant for the ecosystem structure,
as it may hybridize with the ancestor species teosinte,
while the real danger of the hybridization of weed Brassica
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species is mainly relevant for agriculture as it may render
them resistant to herbicides. The problem here is that gene
flow evaluations are based on pollution probability studies,
forgetting the fact that even low levels of pollen can flow to
a few unintended GM plants can lead to each producing a
large amount of pollen, putatively polluting neighbouring
plants. Anyway the problem about pollution is not in my
opinion health related but property related, as leading
companies can sue any owner of a field having, without his
will, even very few GM plants, according to the industrial
patents covering all fields containing any amount of the
patented objects.
Much more relevant are, in my opinion, the side-effects
on ecosystems and particularly on the soil animal and
microbial flora, both extremely relevant factors for the life of
the highly inter-connected agro-ecosystem. On the contrary,
as already discussed by Ch. Darwin in his treatise on worms,
plants are connected through reciprocal exchange of nutri-
tional components with the microbial flora and fauna, both
liable to be affected by all agricultural practices from the use
of chemicals, soil management, water distribution, etc. For
this reason, the impact of GMOs will not only derive from
the plant itself but also from its exudates and the agricultural
practices to which single genetically modified plants
(GMPs) are connected. In the case of GMPs resistant to
herbicides, for instance, the effects of the herbicide itself
(particularly glyphosate and the adjuvants present with it in
commercial preparations) should be considered in all details
in a holistic way, as summarized in an excellent review by
Huber 2010, a very good example of risk evaluation through
the integrated analysis of all the interactions with the plant
itself, the nutrients in the soil and the soil microflora (on that
subect, see also the review by Kremer and Means 2009). As
far as the Bt GMPs are concerned, as thoroughly discussed in
a recent review by Icoz and Stotzky 2008, Bt plants showed
changes in the microbial communities’ compositions, both
as far as bacteria and fungi are concerned, and particularly
mycorrhizae, a key group of fungi for plants nutrition
(Castaldini et al. 2005; Giovannetti et al. 2005). All the
examples just quoted are, however, only the direct effects on
the agro-ecosystem of the transgenic plants themselves or of
the agricultural practices associated to their cultivation but,
as I will try to better discuss in my answer to a different
question, the real damage to the ecosystem is not directly
related to the genetic modification but derives from the
economy, particularly of soybean cultivation in very large
areas of developing countries and also of emerging ones,
particularly in Latin America where large forested or tradi-
tionally cultivated areas have been converted to industrial
soybean cultivation with a very relevant loss of the pre-
existing biodiversity.
I shall not comment on the possible future GMPs not on
the market, as I am used, particularly in this area, not to try
to predict the future behaviour of industry and the markets,
the reason being discussed in my response to question 3. In
fact, the presently utilized technology of genetic engineer-
ing has not been improving for a long time; the research
intensity of leading GM Companies has been constantly
reduced. Particularly, no innovation has been introduced to
avoid ‘‘unintended effects’’ of the interactions between the
inserted sequences and the receiving organism, nor has any
technique been developed allowing one to aim the construct
in specific areas of the host genome to avoid the insertion
and negative modification of relevant sequences of the
original DNA. Certainly the lack of progress in those fields
may seem amazing and can be justified only with the fact
that the revenues of the leading companies do not come
from innovation but from the royalties of already existing
GMPs, advertising and stock exchange speculation.
P. Christou:
Gene flow does occur between GM crops and related
weeds and wild species, but the consequences of this pro-
cess are exaggerated. Taking herbicide tolerance first, it is
important to recognize that although herbicide-tolerant
transgenic plants have a selective advantage in cultivated
areas where herbicides are applied, they have no such
advantage elsewhere. Therefore the energetic burden of
producing unnecessary detoxification enzymes and the
genetic burden of possessing inefficient herbicide target
enzymes can often make such plants less fit than their
weedy and wild counterparts, naturally selecting against
them in wild ecosystems where herbicides are not used, or
in rotational agricultural ecosystems where the herbicide is
rotated (Gressel 2002). Weedy species also tend to be more
resistant to insects and diseases than domesticated crops
because they produce toxins that fend off pests and
pathogens. These toxins have been bred out of our crops
because the toxins affect humans, too, which is one reason
crops are more susceptible than weeds to insect pests
(Gressel 2008). Therefore, additional resistance transgenes
have little impact on the fitness of weeds and are soon
diluted from the population (Gressel 2008). In cases where
a real risk is envisaged, such as controlling weedy rice in
monoculture rice paddies, there are adequate technologies
to mitigate gene flow (Gressel 2012). Different species
(transgenic or otherwise) will undergo different levels of
gene flow, so the only rational way forward is to evaluate
them on a case-by-case basis using science-based risk
assessment procedures clearly divorced from any political
interference. The risk assessment must be initiated by the
applicants developing GM crops, and they must supply all
necessary information to the regulatory agencies appointed
to perform such evaluations professionally and impartially
(EFSA 2010). Notwithstanding the above, the fear of gene
flow damaging the environment has resulted in European
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legislation to mitigate gene flow using a plethora of barrier
and distance-related measures (Ramessar et al. 2010;
Morris and Spillane 2010). Molecular biologists have also
been encouraged to develop strategies to prevent gene flow
by developing systems for selectable marker excision
(Hare and Chua 2002). Ironically, the focus on gene flow
means that little is being done to prevent or control the
introduction of exotic and potentially invasive species,
which in principle could be far more damaging than new
varieties (including GM varieties) of the domesticated
plant species currently under cultivation. A 10-year study
in the UK demonstrated that GM corn, potato, rapeseed and
sugar beet lines are no more invasive or persistent than
their conventional counterparts (Crawley et al. 2001).
GM crops are currently submitted for risk assessment on a
case-by-case basis using science-based risk assessment pro-
cedures, and it is acknowledged that (as with all other tech-
nologies and, indeed, in all other areas of life) we cannot expect
zero risk. Some modifications could be irreversible and the
question is then whether it might be prudent to accept a ‘‘very
low risk’’ of ‘‘irreversible hazardous modifications’’, or follow
the ‘‘zero risk approach’’ as contemplated by a number of
environmental organizations. It might therefore be instructive
to address this theoretical scenario. The reversibility of the GM
trait is influenced by the competitive advantage under natural
conditions conferred by the introduced trait and the ability of
the GM plant to transfer such traits to wild plants. Neither of
these risk factors has been found in the GM crops cultivated in
the EU or any of the crops that have received a positive EFSA
Scientific Opinion. The target of ‘‘zero risk’’ to the environ-
ment as enshrined in the current EU legislation for GMOs
would be sound if agriculture in its entirety were a ‘‘zero risk’’
activity for humans, but this is not the case. However, the
approval delays in the EU do pose a definitive and quantifiable
risk for the safety of humans and the environment as they
contribute to the perpetuation of older and less safe technolo-
gies, such as the use of chemical pesticides.
The focus on risks also draws attention away from the
clear environmental benefits of GM crops, including the fact
that herbicide-tolerant crops allow the adoption of reduced
tillage and conservation tillage practices, increasing carbon
retention in the organic matter of the soil, restoring popula-
tions of organisms living or nesting in the soil, e.g. earth-
worms, ants and birds (Tebru¨gge 2010; Belmonte 1993), and
reducing the use of fuel needed for tillage operations
(Service 2007; Brookes and Barfoot 2009). Similarly,
pest-resistant GM crops expressing Bt proteins are envi-
ronmentally beneficial because there is no need to spray
broad-spectrum pesticides onto the plants, thus reducing the
use of fuel and avoiding environmental contamination with
chemical pollutants (Smale et al. 2009), a strategy that also
benefits non Bt-corn growers (Hutchinson et al. 2010). Bt
toxins are highly specific and are confined within the plant so
that only pests actually attacking plants are affected, not
beneficial insects and microbes. Bt toxins are therefore rec-
ommended for more sustainable integrated pest control
programs (Romeis et al. 2006; Sanahuja et al. 2011). It is
again ironic that detractors focus on the theoretical risks of
gene flow from pest-resistant crops (theoretical because
Bt-crops have a 100 % safety record in the 15 years since
they were first planted commercially (Sanahuja et al. 2011))
while ignoring the much greater environmental burden of
broad-spectrum insecticides that essentially wipe out the
entire insect ecosystem in an agricultural setting and are well
known to be toxic to humans (Sanahuja et al. 2011). The
impressive safety record of Bt crops is unprecedented, yet Bt
crops in Europe are subject to draconian rules which even the
EC has admitted make no sense (Ramessar et al. 2008a,
2009; Sanahuja et al. 2011).
Soil animal and microbial flora are very important fac-
tors for the agro-ecosystem, so it is important to ask
whether GM crops have a negative effect on soil organ-
isms. All peer-reviewed studies published thus far clearly
demonstrate that any effect of GM crops on soil microbial
flora is lower in magnitude than effects related to location,
seasonal variations and (most importantly) conventional/
organic agricultural practices such as tillage. EFSA con-
cluded in its Opinion for continued cultivation of MON810
in the EU (The EFSA Journal 2009 1149, 1–85): ‘‘The
EFSA GMO Panel is of the opinion that potential effects on
soil microorganisms and microbial communities due to
corn MON810 if they occur, will be transient, minor and
localised in different field settings and are likely to be
within the range currently caused by other agronomic and
environmental factors.’’ This conclusion on the safety of
MON810 corn has been confirmed in recent papers on the
impact of Bt corn on endophytic bacteria (Prischl et al.
2012). The impact of the herbicide glyphosate on NK603
corn mycorrhiza has also been found to be lower than
conventional herbicides (Barriuso et al. 2010, 2011a), and
does not change the corn rhizobacterial communities
compared to those in untreated soil (Barriuso et al. 2011b).
2. The introduction of foreign genes into food plants has
been considered to have an unexpected and negative
impact on human health, in particular for the intro-
duction of new allergens and/or for the effects of
possible horizontal gene flow or any other unknown
and uncontrollable effect of the transferred gene. On
the other hand, future GM organisms are likely to
include plants with increased nutrient levels, plants
producing pharmaceutically important molecules and
plants with improved resistance to diseases, cold, or
drought, thus suitable for increasing food security in
disadvantaged areas. Are GMOs, then, a risk or a
potential benefit for human health?
258 Genes Nutr (2013) 8:255–270
123
P. Christou:
GM food crops were first planted commercially in 1996
and in 2010 they were cultivated on 148 million ha of land
(James 2010). In all that time there has been not one single
report of an adverse event caused by the consumption of
GM food products; no reports of toxicity or allergenicity.
Indeed, no difference in nutritional or organoleptic prop-
erties compared to the non-GM equivalent [have been
reported] at all. Several widely discussed reports about the
potential adverse effects of GM crops in animal studies
have also been comprehensively debunked (Sears et al.
2001; Shelton and Sears 2001; Ricroch et al. 2010; Batista
and Oliveira 2009). StarLink is often put forward as an
example of potential toxicity or allergenicity, but it is
important to note that the summary of the investigation by
the US Centers for Disease Control is very clear: ‘‘These
findings do not provide any evidence that the reactions that
the affected people experienced were associated with
hypersensitivity to the Cry9c protein.’’ The details can be
found at http://www.cdc.gov/nceh/ehhe/Cry9Creport/.
More recently, microRNAs from plants were reported to
accumulate in mammalian blood and tissues, where they
‘‘might be able to regulate gene expression’’ (http://the-
scientist.com/2011/09/20/plant-rnas-found-in-mammals/).
The subtitle of this publication, ‘‘MicroRNAs from plants
accumulate in mammalian blood and tissues’’, is grossly
exaggerated. The biological activity was not seen in a
normal diet, but after ingestion of a raw rice diet by rats
equivalent to 33 kg of rice per day for a human. The report
also neglects to mention that microRNAs are a natural form
of gene regulation in all plants and animals, and that
humans therefore consume millions of plant and animal
miRNAs every day in normal diets without any known
effect. Furthermore, the pharmaceutical industry has
struggled for over a decade to develop oral medications
based on RNA-mediated gene regulation without success,
because it is extremely difficult to persuade the human
body to absorb these molecules in a functional form
because of the significant degradation that takes place in
the gut. It is interesting that reaction to this report has
immediately focused on the potential for negative effects
while leaving out an important potential application of
microRNAs: ‘‘Although the team has still a long way to go
in elucidating the mechanisms by which plant microRNAs
can regulate gene expression in humans, these initial results
promise to increase the understanding of how specific
ingredients in food can mediate health and disease’’. This
was a statement by Clay Marsh, Director of the Center for
Personalized Health Care at the Ohio State University
College of Medicine, who studies microRNA expression in
human blood but was not actually involved in the research
discussed above.
Despite the extraordinary safety record of GM crops,
GM agriculture as a whole faces the most restrictive reg-
ulatory framework outside the nuclear industry (Ramessar
et al. 2008a, 2009, 2010). This dogmatic requirement for
‘‘zero risk’’ is astonishing when one considers that all other
technologies and activities in the human sphere of exis-
tence, including nuclear energy, are considered as part of a
risk/benefit trade-off. For example, all known drugs have
adverse effects but are accepted because they have a ben-
eficial role in treating disease, many (natural) foods have
well-known adverse health effects yet people consume
them anyway, and other allergenic plant-derived products
are accepted without question—for example, approxi-
mately 5 % of the world’s population are allergic to natural
rubber but there is no crusade to have this substance ban-
ned and the plantations destroyed (Sussman et al. 1991).
The central issue with GM crops is that because there are
no concrete adverse effects for people to quantify, they can
only focus on theoretical and largely unquantifiable ones.
The hysteria about horizontal gene transfer is a key
example of this phenomenon (Twyman et al. 2009). It is
well known that genes can be transferred horizontally
between bacteria, and from bacteria to higher plants (one of
the methods scientists use to transfer DNA to plants
exploits bacteria). There is no evidence that antibiotic
resistance transgenes have transferred horizontally from
plants to bacteria that are human pathogens, therefore
placing human health at risk, but no scientist can claim
such an event is impossible, so there has to be a small but
non-zero theoretical risk (in the same way that there is a
small but non-zero theoretical risk that someone walking
down the street may be struck by a piano falling from a
cargo plane). However, on the basis of infinitesimal theo-
retical risk, the use of antibiotic resistance genes as
markers in GM plants is now strongly discouraged (Ram-
essar et al. 2007). The great irony is that these antibiotic
resistance genes are themselves entirely natural and are
present in billions of bacteria all over the world. Every time
someone eats non-GM fruits and vegetables, they are
consuming these bacteria and the genes they contain. As
stated above, gene transfer between bacteria is a well-
known and very common natural occurrence so, again
theoretically, these natural bacteria would provide a much
more likely source of antibiotic resistance to transfer to
human pathogens in the gut, yet this process has never been
documented (Ramessar et al. 2007). Finally, the selective
antibiotics are no longer used in a clinical setting, so even
if resistance did jump to human pathogens, it would have
no impact at the point of care. Even so, millions of euros
were invested into the development of politically expedient
technologies to remove antibiotic resistance markers, thus
ensuring the risk of transference from GM plants was
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reduced from almost zero to zero, when nature teems with
the very same antibiotic resistance genes and no steps are
taken to avoid them. There are no other technologies that
demand zero risk, certainly none with such impressive
credentials that the EU could state in a report following a
15-year study (1985–2000) involving 400 public research
institutions and costing 70 million euros: ‘‘… genetically
modified plants and products derived from them present no
risk to human health or the environment……these crops
and products are even safer than plants and products gen-
erated through conventional processes’’ (EC Research
2001; Kessler and Economidis 2001). In a subsequent report
covering the next decade, the EU commission affirmed this
outcome and reiterated: ‘‘The main conclusion to be drawn
from the efforts of more than 130 research projects, cov-
ering a period of more than 25 years of research, and
involving more than 500 independent research groups, is
that biotechnology, and in particular GMOs, are not per se
more risky than e.g. conventional plant breeding technolo-
gies’’ (European Commission 2010a).
As with the first question, the focus on imperceptible risks
means that the many potential benefits of GM agriculture are
ignored. It is generally acknowledged that first-generation
GM crops provide higher yields with fewer inputs (princi-
pally fuel and pesticides), which has important economic
benefits for the agricultural industry in the industrialized
world, but the more significant positive effects are seen in the
developing world where GM crops allow subsistence farm-
ers not only to survive but to take surplus produce to market,
providing additional wealth that supports education,
improves access to medicines, and leads to the empowerment
of women (Christou and Twyman 2004; Yuan et al. 2011).
However, the hysterical anti-GM activism and the resulting
political expediency is seriously delaying this process, par-
ticularly by holding back the deployment of newer first-
generation GM crops that are protected from drought,
salinity and better suited to grow in hostile environments, as
well as second-generation GM crops that have enhanced
output traits such as better nutritional composition (Farre
et al. 2011b). The industrialized world has the luxury of
choice, at least for the time being, but in the developing world
GM crops could turn the tide against plant diseases and pests,
eliminate damaging agricultural practices, reduce hunger
and malnutrition and produce cheap medicines in response to
some of the world’s most pressing socioeconomic concerns
(Farre et al. 2010; Go´mez-Galera et al. 2010). It is no
exaggeration to say that the anti-GM precedent currently set
by Europe is indirectly contributing to death on a massive
scale in Africa and Asia (Potrykus 2010).
M. Buiatti:
When I am asked this question I usually answer that I do
not know for sure and the reason for this answer is that
control agencies are not reliable. I do not frankly know
exactly what happens in all countries, but I believe it to be
similar to what we have here in Europe with EFSA, which I
do know fairly well. The main problems with EFSA are
two. In the first place, EFSA does not utilize independent
laboratories for the control of GMO bio-safety, and there-
fore relies on the answers from the producer companies to
the questions posed by specific scientific committees.
Therefore, while those committees are, as far as we know,
quite independent, of course companies certainly are not
and, moreover, they keep sending back the conclusions of
their laboratories and not the raw data. Therefore it is also
impossible to check the reliability of the statistical treat-
ment of the results, as happened in the unfortunate case of
the Maize MON863. In that case the producing company
(Monsanto) was obliged by a German Court to release the
data, and I personally saw the amazingly poor statistical
treatment utilized. In the second place, EFSA guidelines do
not take into account the rapidly improving tools for risk
assessment and do not carry out what is called ‘‘whole
cycle analysis’’, looking at all possible direct and indirect
effects of GMOs not only on human health, but also on
environment and agriculture as has been rightly done in the
present questionnaire. So, at the molecular level whole
genome analyses putatively leading to ‘‘unintended
effects’’ are never carried out and old fashioned Southern’s
are readily accepted in their place, proving the presence
and integrity of the engineered construct but not the puta-
tive presence of other DNA fragments scattered into the
receiving genome as found in many cases, for instance, by
Svitashev and Somers (2001) and many others. This
omission does not allow the screening of putative changes
in host gene expression, the transcription of fusion RNAs
and proteins, etc. (see Rosati et al. 2008). Moreover, epi-
genomic analyses are not requested, studies on the meta-
bolomes and physiological changes, particularly in
hormone patterns, the study of effects on the environment
are limited to the possible weed resistance to herbicides,
and so on. Finally, requested studies of GMO toxicity in
rats are very poor and carried out for periods that are much
too short. However, my feeling (not my scientific opinion
due to the lack of data) is that health risks of transgenic
food on the market now are limited, micro-RNAs may in
theory block genes having complementary sequences. I
think that the risks from blocks in genes relevant to human
health is very low, but it may happen. It should be recalled
from this point of view that not-aimed insertion of DNA
into the receiving genomes is the main reason of the
unfortunate failure of gene therapy in humans. The real
danger being, also in this case, glyphosate and its adju-
vants. As far as the future is concerned, I am really
extremely worried about open air cultivation of plants
which are transgenic for pharmaceuticals, because in that
260 Genes Nutr (2013) 8:255–270
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case cross-pollination with vaccines or other proteins could
be really dangerous, as it could lead to unneeded phar-
maceuticals in food. Of course, on the other hand, plants
transgenic of proteins not liable to be produced by pro-
karyotes, if the plants are not to be grown in open air, may
certainly be interesting.
3. When judging a novel technology the first question
to be answered is whether the technology is really
innovative and successful.
Which are the major technical advancements in plant
genetic engineering since the release into the market of the
first genetically modified products?
P. Christou:
The first GM crops on the market were engineered for
herbicide tolerance; these were soon followed by plants
engineered for pest resistance. More than 15 years later,
almost all commercially approved GM crops still have one
or both of these traits, and for the first time in 2009–2010,
plants stacked with multiple traits were grown more widely
than those with single traits. Indeed, July 2009 saw the
commercial release of the most ‘stacked’ GM crop thus far,
i.e. Smartstax corn, jointly developed by Monsanto and
Dow AgroSciences, combining eight different herbicide
and pest resistance traits.
Despite the rather limited scope of current commercial
GM crops, the development pipeline is incredibly rich and
diverse. Innovations in the development of GM crops fall
into four major areas, which can be described as improved
first-generation crops (focusing on input traits but using
innovative approaches), novel second-generation crops
(delivering better output traits), third-generation crops
(delivering value added products) and technical develop-
ments such as the control of transgene expression (Farre
et al. 2011a; Bai et al. 2011).
In the first category, several new approaches have been
developed to achieve pest resistance in addition to the current
reliance on Bt genes, because Bt genes do not exist to counter
the effects of all known pests. Also, there is the potential for
pest populations to evolve resistance to single Bt toxins
(Christou et al. 2006; Ferry et al. 2006). As well, there are
alternative protein toxins such as lectins that work against
recalcitrant sap-sucking insects; novel approaches include
the expression of toxin fusions (Mehlo et al. 2005) and the use
of RNA interference by targeting genes essential for insect
development (Huvenne and Smagghe 2010). A small number
of commercial crops are resistant to diseases, such as virus-
resistant papaya, squash, plum and bean plants, and rice
plants resistant to bacterial infections. Many additional GM
crops resistant to various viral, bacterial and fungal diseases
are under development, using a vast number of different
approaches, such as enhancing natural plant defenses, the
expression of pathogen proteins, the expression of plant-
proteins that repel specific pathogens and even the expression
of mammalian antibodies that neutralize pathogens inside the
plant (Collinge et al. 2010). Many concepts have also been
developed that will help crops withstand harsh environments,
especially drought, high levels of salinity, waterlogging and
poor soil quality (Cominelli and Tonelli 2010).
Although first-generation crops benefit farmers mainly
by allowing them to overcome biological and environ-
mental extremes (biotic and abiotic stresses), the next
breakthrough in GM agriculture will be the deployment of
second-generation crops, where the benefits are targeted at
consumers. The key examples here are Golden Rice, which
produces enough b-carotene in the polished grain to ensure
that consumers relying on a cereal diet do not suffer vita-
min A deficiency (Potrykus 2010), and the multivitamin
corn and high zeaxanthin corn produced in our laboratory
(Naqvi et al. 2009, 2011a, b; Zhu et al. 2008). In multi-
vitamin corn, three distinct metabolic pathways are modi-
fied to simultaneously enhance the levels of three key
vitamins. The rapid progress of nutritionally enhanced GM
crops through the development pipeline will save millions
of lives and reduce the impact of malnutrition in the
world’s poorest areas (Zhu et al. 2007).
There has also been remarkable progress in the devel-
opment of third-generation GM crops, which are not
intended for human consumption but instead have valuable
industrial uses (Naqvi et al. 2011a; Ramessar et al. 2008c).
At the forefront are pharmaceutical crops producing pro-
teins or small-molecules of medical relevance (Ma et al.
2003, 2005; Ramessar et al. 2008c). In our laboratory we
have achieved the production of an HIV-neutralizing
antibody in corn which could be used as a microbicide
component to help prevent the spread of the virus (Ram-
essar et al. 2008b). The value of producing such molecules
in plants rather than mammalian cells or bacteria as is
usually the case is the reduced costs, the better safety
profile (no human or animal pathogens, no endotoxins) and
the massive production scale that can be achieved with
little additional effort (Stoger et al. 2005). Also in this
category are plants used to produce industrial raw materials
(e.g. starch, rubber) and plants used to produce fuel (e.g.
bioethanol, biodiesel). In both cases, it is important to
avoid competition with food crops.
Finally, a variety of novel technologies have been devel-
oped to control transgene expression, e.g. spatiotemporal and
inducible promoters (Peremarti et al. 2010), and to increase
the precision of transgene integration into plants, e.g. tran-
scriptional activator-like effector nucleases (TALENs) and
zinc-finger nucleases (Weinthal et al. 2010).
Some might argue that the development pipeline dis-
cussed above is misleading because only four cultivated
crops with the same two modifications have reached the
Genes Nutr (2013) 8:255–270 261
123
market. Does this then mean that all the others have been
failures? I would say that the answer is emphatically no.
First, there are other products on the market that do not
receive as much attention, e.g. virus-resistant rainbow
papayas that have been consumed in the US for years and
that have recently been approved in Japan, one of the most
stringent markets. GM sweet corn is also approved for
human consumption in the US and GM beans are now
grown in Brazil. The problem with the adoption of novel
GM crops is the huge cost of regulatory approvals (industry
estimates suggest each new crop will cost $US 100 million
in development). This means that only major staple crops
currently offer any hope of investors recovering their R&D
costs. Although the EU claims to defend a ‘‘knowledge-
based bioeconomy’’, some patents covering glyphosate-
tolerant sugar beet expired before the cultivation of this
crop was approved in Europe. On top of this, the activity of
NGOs that oppose GM crops is often supported by public
administrations and welcomed by the media, resulting in
approved GM crops like Bt potato being rejected by the
food industry to avoid campaigns against their brands. We
can define them as technical and regulatory successes, but
marketing failures, as happens in many other areas of the
economy.
Golden Rice will soon be grown on a large scale in the
Philippines. It has taken years to obtain regulatory approval
and funding for this was raised only recently. Because
Golden Rice does not directly benefit farmers, there was no
incentive for industry to cover the approval costs. My
opinion is that these costs should have been covered by
government public health authorities, as they stand to lose
the most from a population riven by vitamin A deficiency
and they have the most to gain from the health benefits
derived from this crop.
M. Buiatti:
After the development by M.D.Chilton in 1991 of the
first method of plant genetic engineering through the usage
of Agrobacterium tumefaciens, the first transgenic plant
(tobacco), was produced in 1983 and a few years later Bt
genes for resistance to insects and genes for the resistance
to herbicides were introduced into crops. The first trans-
genic cultivar to enter the market was the Tomato Flavr
Savr, resistant to rotting, in 1994, but it was very soon
withdrawn, because of unexpected negative side effects of
the transformation. In 1996 both insect resistant maize and
RR soybean herbicide resistant plants were introduced into
the market. As reported by Clive James in the annual
review of cultivated GMPs in 2010, only four cultivated
crop plants, still bearing the same two modifications, are in
the market and have been widely commercialised (soybean,
maize, cotton, canola). Therefore no new products have
been released in the market with success, in spite of the
many announced GMPs, and a few have been withdrawn
from the market like the first one, the tomato Flavr Savr
and the last one as far as I know, the so-called ‘‘Golden
rice’’, of which a new cultivar producing more pro-vitamin
A than the former is expected but has not been released. In
the meantime, research intensity on the part of the leading
companies has been decreasing as discussed by Schim-
melpfennig et al. (2004). Obviously, this speaks very little
for an innovative technology whose first products have
been on the market for almost 15 years. The scientific
reasons for these failures lie in the complexity of the plant
system and the consequent ‘‘unintended effects’’ deriving
from the aforementioned interactions between the inserted
construct and the host plant. Of course this does not mean
that new useful and efficient products could not be
obtained, but this can occur only if new, reliable methods
of control of the dynamics of the plant system are devel-
oped. Apparently and unfortunately, the leading companies
do not seem interested in following this process, probably
because, as discussed further in the answer to question 6,
incomes of leading companies derive from the control of
the market, the intellectual property rights of the com-
mercialised products, the stock exchange etc. and not from
innovations in the field.
4. The import of affordable GM soybeans and GM corn
from Brazil, USA, Argentina and other countries is
pivotal in maintaining the competitiveness of the
livestock farmers that satisfy the consumer’s demand
for meat, milk and eggs. This supply is allowed by EC
approval and supported by positive case by case EFSA
Scientific Opinions and up to 16 years of environmen-
tal compatibility. Since EFSA has issued a positive
Opinion on the cultivation of GM crops in the EU,
what reasons can be provided to discriminate against
European farmers who are not allowed to cultivate the
same GM crops that are imported and consumed from
other continents?
M. Buiatti:
As discussed thoroughly also in the answer to question
6, this question is misleading when it states that livestock
farmers need GM-soybean They need soybean, but it need
not necessarily be transgenic. (a) As shown by USDA data
on productivity of soybean in the U.S.A soybean produc-
tion per acre steadily increased from 1977 to 2007 and the
speed of increase did not change with the introduction of
GM plants in 1996. (b) From the nutritional point of view,
as far as we know (see answer to question 2) no data are
available showing better results in animal feeding in the
case of GM compared with non GM soybean. The reasons
most of world wide soybean production stems from GM
plants is the economic advantage coming from a reduction
262 Genes Nutr (2013) 8:255–270
123
in the needed manpower for herbicide spraying on herbi-
cide resistant cultivars and the control of the market by the
three large holdings: Monsanto, Dupont and Syngenta. In
our case the average size of farms is of 5–6 hectares; the
farms with the extant GMPs may be up to more than
hundred thousand. So, while in large farms airplanes can be
utilized to spray herbicides, certainly our farmers have to
rely on manpower working directly in the field. So here and
in most anti-GMO European regions there is no manpower
advantage.
P. Christou:
There is no rational explanation for the EU’s current de
facto ban on the cultivation of GM crops while concur-
rently allowing the import of GM produce from the
Americas to prop up the meat, poultry and dairy industries.
The EU is a net importer of agricultural raw materials
and 55 % of these imports come from ten countries, most
of which have GM-based agricultural industries (Sabalza
et al. 2011). Brazil, the United States and Argentina occupy
the top three positions and are also the world’s largest GM
producers, and almost all of the products imported from
these countries are GM. The EC has recently proposed to
give Member States the freedom to veto the cultivation of
GM crops on their own territory without needing to provide
any scientific evidence relating to new risks (European
Commission 2010b), ostensibly to prevent tactical voting
leading to EU-wide bans (Casassus 2011). However,
although the proposed amendment will allow member
states to adopt measures against the cultivation of GM
crops, they will not be allowed to prohibit the import or
marketing of authorized GM products from elsewhere,
which means that EU markets are likely to be flooded with
imported GM products that could just as easily be home-
grown. This is clearly a ludicrous position, which simul-
taneously restricts the freedom of EU farmers to grow the
crops they choose and forces them to accept GM animal
feed from abroad (Sabalza et al. 2011).
Even so, the import of GM products is also over-regu-
lated, and this is particularly apparent in the EU’s treatment
of imported corn and soybean from the United States,
which has radically different regulations concerning
adventitious presence limits, traceability and labeling
(Ramessar et al. 2008a). Although the EU is deficient in
feed protein and is ultimately dependent on soybean
imports, the complex and onerous process for approving
imported GM products has discouraged overseas traders,
resulting in a decline in imports from $2.8 billion in 1997
to $1.9 billion in 2008 (USDA 2009). This is despite EFSA
issuing multiple Scientific Opinions declaring that GM
products are safe and (as discussed above) the complete
absence of any adverse effects of GM crops anywhere in
the world throughout the 15? years of cultivation.
A critical point is that if the EU continues to obstruct
GM agriculture, it will force farmers to use environmen-
tally hazardous, expensive and unsustainable agricultural
practices, spend unnecessary resources on fossil fuels and
agrochemicals, while at the same time importing GM
products from the Americas. This policy will also dis-
courage research and drive researchers overseas where the
value chain can be realized in terms of released GM crops.
Within the EU, researchers working on GM plants know
that the best they can expect for their products is green-
house cultivation, and that despite their benefits, GM crops
are unlikely to be deployed in any setting where they could
perform a useful function. Here the EU policy on GM crops
is attacking its own foundations as a competitive bioec-
onomy because with one hand the EC offers funding for
innovative biotech research and values (or even requires)
the participation of small- to medium-sized enterprises
(SMEs) and large industry partners, while with the other
they prevent the same companies from realizing the value
of their development pipeline. Many individual scientists
and large companies with ambitious GM research projects
have moved abroad to continue their work, and promising
European SMEs have been unable to find investment
partners (The Guardian 2003, 2004). No significant
investment in Europe is likely unless companies can recoup
their R&D costs by selling their products to farmers. The
attitude of European policymakers reveals the immense
divide between the rational evaluation of science and
business, and the panicky, expedient politics pandering to a
populist media and activists (Farre et al. 2010, 2011a, b).
5. It is known that uncontrolled attacks of corn borers
(Ostrinia, Sesamia) facilitate the growth of Fusarium
moulds in corn grains leading to the accumulation of
dangerous levels of fumonisins. The use of Bt corn has
been proven to decrease/eliminate fumonisins from
corn, and this is a contaminant that has led to European
safety alerts and corn product recalls. What is your
recommendation to reduce/eliminate mycotoxins in
corn grain?
M. Buiatti:
Of course there are more conventional methods to stop
the attacks both through the use of chemicals and of bio-
logical agents, but certainly insect resistance may be a
valid one when and if the plant is resistant to all corn borers
at the same time and not only one of them, and of course
the borers are not naturally selected for resistance to Bt
toxins. Everybody who has been working in plant breeding
knows that both in the case of ‘‘traditional’’ breeding and
genetic engineering, insect resistant crops are resistant only
for a short time because insects acquire resistance to the
toxins in the case of genetic engineering or other genes
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leading to resistance in traditionally bred cultivars. This is
happening in the case of maize in the USA and induced the
Government to rule the maintenance of areas with sus-
ceptible plants to partially overcome this problem. In the
case of cotton in China, the resistance to the boll worm
induced the multiplication of more than a hundred com-
petitor species, and therefore the amount of insecticides
rose to levels never reached with non-boll worm resistant
crops
P. Christou:
Fumonisins are mycotoxins produced by Fusarium
molds when they colonize cereal grains. They are toxic to
humans, particularly affecting liver and kidney functions,
causing esophageal cancer, increasing HIV transmission
rates (Williams et al. 2010) and inducing neural tube
defects such as spina bifida in utero (Marasas et al. 2004;
Torres et al. 2007). The maximum tolerable daily intake
is 2 lg/kg body weight as stated in EC Regulation
1881/2006. Many nations have established regulatory
standards stating maximum tolerance levels for mycotoxins
in food and feed. Therefore, aside from the health risks
described above, mycotoxin contamination can also reduce
the price paid for food crops, or in extreme cases, can cause
market rejection of entire food or feed shipments (Wu et al.
2004; Wu 2006). The maximum permitted daily intake of
fumonisins was doubled in EC Regulation 1126/2007 in
recognition of the fact that recommended levels cannot be
achieved under some circumstances. This is not a recom-
mended practice, nor is it consistent with other EC deci-
sions including the application of the precautionary
approach, because several corn herbicides have been ban-
ned in the EU at contamination levels far lower than
allowed for fumonisins (Wu 2006).
There is a clear relationship between corn borer damage
and unsafe levels of fumonisins in raw corn, reflecting the
penetration of damaged corn kernels by the fungus
(Munkvold et al. 1997; Arin˜o 2009; Escobar and Quintana
2008; EFSA 2005). Any method that reduces insect dam-
age in corn also reduces the risk of fungal contamination,
but foliar Bt sprays are not sufficient because the corn
borers are protected inside the cob (Sanahuja et al. 2011).
Bt corn confers resistance to corn borers and therefore
reduces mycotoxin contamination. In Europe and else-
where, field trials of Bt corn on 288 separate test sites have
shown that harvested kernels have significantly lower fu-
monisin levels than non-Bt counterparts, with fumonisin
concentrations in Bt grain usually lower than 4 lg/kg and
often below 2 lg/kg (Wu 2006). Interestingly, 31 % of fu-
monisin contamination alerts in Spanish corn grain represent
organically-grown corn, which represents less than 1 % of
the area under cultivation, and the other 69 % represent
conventional corn. No alerts have been raised for borer-
resistant GM corn, which represents 21 % of the cultivated
area. This information comes directly from the Spanish
Ministry of the Environment (http://www.efsa.europa.
eu/en/events/documents/gmo090914-p13.pdf).
Similar indications come from import checks in Italy
where contamination in Bt corn is consistently registered as
lower than conventional corn. The benefit of Bt corn in
terms of the reduction of mycotoxin damage has been
virtually ignored in policy debates, despite its positive
economic impact in the US and its effect on both health
and the economy in developing countries (Wu et al. 2004;
Wu 2006). In my opinion its cultivation should be man-
datory in EU regions where corn borers are endemic, but
the cultivation of Bt corn is subject to a de facto ban across
large areas of the EU and particularly for nations such as
Italy (Table 1) and France where fumonisin toxicity is
prevalent (Pietri and Piva 2000; Masoero et al. 1999;
Folcher et al. 2010).
6. Roughly one quarter of the Earth’s terrestrial surface is
now under cultivation with more land converted to
crop production in the 30 years after 1950 than in the
previous 150 years. Given this picture, economic and
social concerns present critical challenges to agricul-
ture in the next decades. Farm profitability, viability of
rural communities, fair trade and agricultural labor
represent significant issues. Which are the advantages
of GM crops for agriculture from the economic and
social points of view?
P. Christou:
GM crops provide tools that are compatible with many
of the other approaches used currently to increase food
production, while reducing the environmental footprint of
agriculture and increasing the affordability of crops
(Christou and Twyman 2004). The socioeconomic advan-
tages of GM crops are demonstrated by the consistent
growth in adoption since the first commercial releases
(James 2010) combined with ample evidence of greater
farm profitability in both developed economies like the US
(Smale et al. 2009) and emerging economies like India
(Subramanian and Qaim 2010). There has been consider-
able debate about economic potential of GM crops in
developing countries (Park et al. 2011), and an extensive
analysis carried out by Brookes and Barfoot (2010) showed
that approximately two thirds of the net benefits of GM
agriculture go to farmers, and one third to the seed supply
chain. In the case of Bt crops, these benefits include yield
improvements, higher revenues and lower pesticide costs,
which more than compensate for the higher seed prices.
Overall, the available evidence confirms that in both
developed and developing countries, the adoption of GM
crops can increase the farmer’s income. The increase in
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income to small-scale farmers in developing countries can
have a direct impact on poverty alleviation and quality of
life, a key component of sustainable development. Bennett
et al. (2006) compared the performance of Bt and non-Bt
cotton in resource-poor smallholder cotton farm plots in
India and South Africa. Their results demonstrated that in
many agricultural environments the adopters of Bt cotton
benefit in terms of higher yields, reduced labor and pesti-
cide use, and ultimately higher gross margins per hectare,
leading them to conclude that ‘that the smallest producers
are shown to have benefited from adoption of the Bt variety
as much as, if not more than, larger producers.’
Even where economic issues of coexistence come into
play, smallholder farmers usually trade their GM and non-
GM crops together, using cooperatives or local dealers that
also provide seeds and other inputs. In this way, in corn-
borer endemic areas where Bt-corn is approved and its use
makes sense, it is common to see 50–80 % of farmers using
GM corn, without isolation barriers and only the required
refuges of non-GM corn to delay the appearance of resis-
tant corn borer strains. These jointly marketed products are
labelled as GM corn even if only 50–80 % of the grain is
transgenic.
The social impact of GM agriculture is intertwined with
the economic benefits because the higher margins gener-
ated by GM crops help efforts to alleviate poverty, and
therefore provide better access to food, medicine and
education, enhancing the social dimension of sustainability
(Yuan et al. 2011). Second- and third-generation GM crops
have been developed to address these issues directly by
improving nutrition or providing inexpensive drugs, but
even the first-generation crops have indirectly led to
improvements simply by increasing the profitability of
farms and empowering the smallholders in a socioeco-
nomic context. There have also been more direct health
benefits of GM agriculture by reducing exposure to pesti-
cides (Brimner et al. 2005; Knox et al. 2006), changing the
patterns of herbicide use to favor those with lower toxicity
such as glyphosate, and as mentioned above, reducing the
exposure of populations to mycotoxins (Munkvold et al.
1999). Work is also well advanced in the development of
GM crops that will have a direct impact on health, e.g.
those with reduced allergens (Chu et al. 2008), higher
levels of proteins and carbohydrates (reviewed by Newell-
McGloughlin 2008), and higher levels of essential amino
acids, essential fatty acids, vitamins and minerals (Damude
and Kinney 2008), the most prevalent examples being
Golden Rice (Potrykus 2010), multivitamin corn (Naqvi
et al. 2009; Zhu et al. 2008), and high zeaxanthin corn
(Naqvi et al. 2011b). GM agriculture can therefore have a
significant impact on both industrialized and developing
economies by increasing farm profit margins, as well as by
contributing to the social dimension of sustainable devel-
opment by reducing the handling and use of pesticides,
exposure to adventitious mycotoxins and, ultimately, by
directly addressing the causes of hunger and malnutrition.
M. Buiatti:
As I mentioned before, the productivity of maize and
soybean, according to USDA data from 1977 to 2007, did
not increase from the introduction of GM-crops but prob-
ably from the improvements in management and conven-
tional breeding. Moreover, in the case of Bt, the advertised
reduction in the usage of insecticides did not happen
because of the selection of Bt resistant insects and the fast
reproduction of other parasite species than those killed by
Cry toxins, as we shall discuss later. Also the cost of
herbicides has not been obviously reduced, the very aim of
herbicide resistant plant introduction being an increased
number of treatments also during plant growth. Therefore,
as already mentioned, the economic advantage of the
introduction of herbicide resistance traits is the reduction of
manpower costs, all this favouring farms of large dimen-
sions with an increase of the input of capital and a decrease
of labour leading to the exit from the systems of subsis-
tence agriculture due to lack of capital. The reasons of the
outstanding success of GM crops particularly in the USA,
Canada and Latin-American countries can be understood
only if we look at the structure of the market for the four
mentioned crops. In the first place, (for a good review, see
Howard 2009) since the nineteen-nineties, a very fast
concentration process has occurred, few multinational
companies gaining the control of large part of the food
related market, the first four companies controlling 59 % of
the pesticides, 56 % of the seed and practically all GMPs.
This process has been favoured by the extension, within the
TRIPS agreement, of industrial patents to living objects
and processes and by the change in the UPOV cancelling
both the so-called farmer’s and breeder’s rights. To give an
idea of the power given to the holders of patents, already in
1995, according to the World Patent Index, Bt maize was
covered by 440 patents, 88 % of which were owned by
industry. Nowadays, three companies, through IPRs, have
the control not only of GMPs but also of innovations
related to other steps of the food production chain. That
follows from the fact that all the leading companies, before
GMO production, were agro-chemical industries and since
Table 1 Fumonisin content in ppb (lg/kg) in Italian field trials
Author Years Bt corn Non-Bt corn
Pietri and Piva (2000) 1997 2.021 19.759
Pietri and Piva (2000) 1998 5.448 31.632
Pietri and Piva (2000) 1999 1.394 3.902
Masoero et al. (1999) 1997 1.970 20.050
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the 1990s acquired control of chemical, pharmaceutical
and seed companies. For instance, Monsanto, a herbicide
producer in the sixties, acquired Pharmacia and Upjohn and
the seed industries Cargill, Dekalb Genetics Corporation,
Delta and Pine Land, Seminis, and Holden Foundation
Seeds and controls more than 200 seed companies in India,
China and Brazil. Dupont, on the other hand, has acquired
the seed company Pioneer High Bred, while Syngenta
derived from the fusion between Novartis agriculture and
Zeneca. The power of the leading companies is also based
on the presence in public control agencies and in the edi-
torial boards of international scientific journals, as thor-
oughly discussed by Glover (2009), on behalf of the
British E.S.R.C., in his critical synthesis of the scientific
literature concerning Bt-Cotton in China, India, South
Africa. For this reason, according to Glover, it is not
widely known that in China BT cotton is useful only in the
case of heavy presence of the boll-worm, that insecticide
consumption does not decrease (Wang 2008). Nor it is
known that in India, in the regions of Andhra Pradesh and
Maharashtra, the presence of 150 different species of
insects obliged the farmers to increase the input of pesti-
cides while the price of cotton was decreasing (Ramas-
undaram et al. 2007). In Latin America, on the other hand,
problems derived from the transformation of local subsis-
tence agricultures based on the production of food into
industrial farming, aimed at the export of soybean for
animal feeding in developed countries. In Argentina,
Brazil, Paraguay and, lately also Uruguay, many small
farms were purchased and replaced by large ones, up to
100.000 hectares. For this reason, in Argentina, soybean
production rose from 1996 to 2004 by 11.8 %, that of
wheat being -2.3 % lower, potato -3.3 %, millet -19.1 %
and labour also being reduced by 50 % (Gallacher 2009).
In Brazil, farmers were expelled with the use of force and
the big soy producers from Argentina along with Japanese
and German jobbers control 76 % of Paraguay soybean
producers, thus further reducing revenues and jobs. Of
course, in all these cases the economic and social disasters
deriving from the introduction of GMPs were not due by
any means to genetic engineering techniques as such, but
by the structure of the market where for the first time
living objects could be covered by industrial patents
through economical and political agreements between the
producer companies and governments and under the rules
of the WTO. However, it is worth stressing here that, as
mentioned before, the advantages of GMPs only favoured
large farms and the multinational companies, small farm-
ers leaving the fields and the seeds of a number of relevant
crops and losing languages and traditional knowledge in
the favelas of several countries (see the data in the website
of Terralingua, an NGO working on bio-linguistic
problems).
7. The possible economic advantages of GMOs in an
agricultural context have been discussed extensively.
In this respect GMOs have been viewed by some as an
effective way to meet the energy needs of the most
vulnerable, malnourished populations in developing
countries. Do the available results provide indications
for a possible role of GMOs in improving food quality,
therefore providing specific nutritional advantages also
in wealthy population groups?
M. Buiatti:
The improvement of nutritional quality of crops has
been one of the main objectives of plant genetic engi-
neering as, in theory, the modification of metabolic path-
ways could lead to the qualitative and quantitative
improvement of specific nutritional components. Rather
unfortunately, due to the network structure of plant
metabolism implying that a change in one node will affect
other components, the results have been far from success-
ful. As far as I remember, the only putative success has
been obtained with the so-called ‘‘Golden Rice’’, a pro-
ducer of pro-vitamin A which was released into the market
but soon withdrawn because of the low level of production
of the molecule. This happened a few years ago and we are
now waiting for new cultivars with improved production.
Unfortunately, as already discussed, the research intensity
of GMO producers has been lower and lower, thus slowing
the release of really innovative cultivars in all fields.
P. Christou:
GMOs certainly have the potential to provide nutritional
advantages for wealthy population groups, despite the
controversy about GM agriculture in Europe discussed
elsewhere in this article. One of the important benefits of
transgenic crops is the ability to generate more nutritious
varieties, and although these are currently targeted towards
developing countries with the worst malnutrition levels,
they offer clear benefits to all sectors of the population.
Even in Europe there is a surprisingly large malnourished
population, which has arisen not only through the impact of
poverty but also through ignorance and poor lifestyle
choices. Malnourishment is particularly rife in the elderly
population because one of the consequences of aging is a
progressive loss of the ability to absorb nutrients
(Ljungqvist et al. 2010).
EU policies on food and nutrition are described in the
European Commission White Paper on Food Safety and the
Program for Public Health (European Commission 2000).
The fortification of processed food and agronomic biofor-
tification using nutrient-rich fertilizers have been applied
successfully to overcome the lower levels of nutrients in
the UK and Finland (Lyons et al. 2003; Broadley et al.
2006), but there are also several sectors of the wealthy
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population where nutritional and food quality needs could
be met through the use of transgenic crops. The most sig-
nificant is the biofortification of cereals, legumes, fruits and
vegetables with iron to combat anemia resulting from iron
deficiency caused by poor dietary habits (Lucca et al.
2002). This is because traditional routes such as iron sup-
plements can be inefficient because of poor compliance
(Darnton-Hill and Nalubola 2002; Go´mez-Galera et al.
2010). Another interesting example is the potential to
increase the carotenoid levels in cereals such as maize to
address macular degeneration in the elderly. Most people
know that b-carotene is required in the diet as a source of
vitamin A, but few recognize the importance of other
carotenoids such as lutein and zeaxanthin, which are
required in the eye to prevent damage caused by strong
light (Landrum and Bone 2001). A diet rich in these
molecules has been linked with eye health in the ageing
population and biofortification at source would be an
advantageous way to address this growing problem
(Hammond et al. 1997; Landrum et al. 1997).
Another valuable approach is the fortification of staple
foods such as cereals with polyunsaturated fatty acids cur-
rently only found in fish. The metabolic pathways that lead to
omega fatty acids are understood and can be recreated in
plants (Ye and Bhatia 2012). The development of cereal
products enriched with these essential fatty acids would
increase the general health of the population by providing
essential nutrients to those who rarely eat fish, and would also
reduce pressure on fish stocks as a sole source of this nutrient.
The controversy surrounding mycotoxin levels in maize is
discussed in another section, but it is worth pointing out here
that this is a problem that faces all consumers, not just those in
developing countries, so the ability to grow Bt maize com-
mercially in Europe would, again, provide consumers from
all population groups with higher quality food and would at
the same time remove the need to import exactly the same
products from abroad (Folcher et al. 2010).
Finally, there is a great deal of interest in the development
of functional foods that provide added-value health benefits
to consumers as well as calories (e.g. antioxidants and other
health-promoting compounds). Since the metabolic path-
ways leading to many of these valuable molecules are now
being unraveled, it is likely that the first generation of bio-
fortified foods containing essential nutrients will be followed
by a second wave of luxury goods aimed at the higher-income
sectors, comprising food products with enhanced levels of
health-promoting compounds (Zhu et al. 2012).
Conclusions
There is obviously no final conclusion of this debate, which
is likely to continue for years. We can foresee that plant
biotechnology will potentially be able to provide several
benefits and address many challenges in food production.
However, it is also crucial that the release of GM crops in
the environment does not bear new risks and irretrievable
consequences and/or threats for human health.
However, within this framework, it would be desirable to
reach a global harmonization of regulation and legislation of
GM crops in order to face the ongoing globalisation of agri-
cultural production. GM crops, in fact, are going to become
significant in world crop production as the cultivation of GM
crops in the world in 2011 reached 160 million hectares
(?8 % with respect to 2010, a 94-fold increase with respect to
1996) in 29 countries worldwide. According to the Interna-
tional Service for the Acquisition of Agri-biotech Applica-
tions (James 2011), 16.7 million farmers grew biotech crops
in 2011, over 90 % were small resource farmers in developing
countries (7 million in China and 7 million in India), and they
collectively planted 14.5 million hectares of GM crops. The
US is the lead producer of GM crops, with 69.0 million
hectares (maize, soybean, cotton, canola, sugarbeet, alfalfa,
papaya, squash) followed by Brazil (30.3 million hectares,
soybean, maize, cotton), Argentina (23.7 million hectares,
soybean, maize, cotton), India (10.6 million hectares, cotton),
Canada (10.4 million hectares, canola, maize, soybean, sug-
arbeet) and China (3.9 million hectares, cotton, papaya,
poplar, tomato, sweet pepper). In Europe, six EU countries
(Spain, Portugal, Czechia, Poland, Slovakia and Romania)
planted 114.490 hectares of Bt maize (?26 % as respect to
2010), with Spain growing 85 % of the total in the EU.
Obviously, this paper is not aimed at reaching any
conclusion on this controversial matter. However, we hope
that this face-to-face between two almost opposite posi-
tions can contribute to the discussion related to this delicate
aspect of agro-food science.
It is worth stating that the debates on international
markets, economical issues, crop productivity, ethical
aspects and environmental concerns are indisputably
important, but only keeping in mind that the first, most
imperative issue is to warrant a reliable, safe and healthy
nutrition to the population.
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